believ syk strong result guidanc support stock momentum
may scrutin syk organ revenu growth guidanc
show think manag simpli set expect
conserv anticip sustain organ revenu growth
gener strong om expans along dd ep growth
exce lofti expect perform think guidanc
strong enough support stock momentum
post organ revenu growth despit face challeng year-
over-year comp easili exceed consensu expect
organ revenu growth repres syk highest organ growth rate
decad knee grew reflect modest sequenti deceler howev
trauma extrem acceler back high single-digit growth surg
neurotech contribut organ growth respect margin
front deliv approxim bp oper margin improv
encourag given dilut integr mean core
busi experienc even higher level expans ep came top end
compani guidanc rang year year
two cent better consensu estim ep result signific
impact fx either translat transact consist syk expect
full-year basi ep increas reflect strong sale growth
believ syk guidanc appropri set suffici pleas investor full-
year compani expect organ sale growth stronger
quarter partli reflect new product launch midpoint
repres deceler organ sale growth believ
simpli leav room perform top end rang compani
target oper margin expans bp year recent acquisit
greater drag margin expans vs bottom line
anticip adjust ep compar current
consensu rang reflect earn growth includ
absorpt cent fx headwind well dilut acquisit
compani expect effect tax rate year forecast
adjust ep vs current street project estim
fx headwind
pleas see page report import disclosur
despit face tough comp previou year deliv strong quarter
orthopaed organ constant currenc growth includ organ growth
intern growth trauma extrem led group growth
mark return hsd growth hip knee deliv
growth respect knee result slight decel sequenti report basi
previou quarter constant currenc result similar result comp
adjust basi manag note strong demand mako total knee platform
product continu drive growth knee busi mako instal
quarter robot ww y/i sequenti competit
account instal occur previou year number
result bring total instal base robot ww
mako result also aid describ posit price tailwind increas
mainten less eros bone cement
medsurg revenu organ growth exceed consensu
estim strength across portfolio consist consensu beat
instrument cc endoscopi cc medic busi unit
manag attribut strength quarter strong commerci execut sever
highlight camera help reacceler endoscopi busi
moder custom anticip launch late novadaq
demonstr stellar double-digit growth medic busi strength
balanc across product line especi strong europ australia emerg
neurotechnolog spine busi deliv revenu organ
ahead consensu estim better expect spine revenu
vs consensu off-set neurotechnolog revenu
street acknowledg integr still earli stage
express high level satisfact progress fourth quarter
sale leadership organiz structur establish along
territori assign pace convert global salesforc hybrid
dealer model end especi encourag manag call
note salesforc manag critic compon success integr
cross-sel product portfolio across spine also earli stage although measur
progress expect balanc first quarter anticip pro-
forma core spine revenu growth mid-singl digit neurotech busi
benefit strong demand stroke cmf neuro power instrument
entellu also continu perform well spine experienc moder price pressur
quarter off-set part tritanium implant growth europ china japan
highlight intern organ growth print
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
orthoped industri risk continu util pressur account
organ play bigger role health care deliveri competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken consum demand develop market
econom and/or polit uncertainti emerg market intellectu properti
deeper util pressur europ competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market fluctuat foreign exchang
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock corp secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc januari et dissemin januari et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
